Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics, Inc. (IKT) — VMCI valuation read

IKT prints VMCI 45/100 inside the Healthcare sector, where the median sits at 50. The 5-point below-median delta is the cleanest single-number summary of Inhibikase Therapeutics, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On IKT, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** IKT trades at 14.0x earnings, 22% below the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 3.3x is the binding constraint on the bear case; that is the risk line for Inhibikase Therapeutics, Inc. on the trailing financials.

IKT fell 0.1% over the trailing 7 days, with a -10.3% read on a 30-day basis.